Torrance, Calif., — May 11, 2015, — Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that management will present its work on sickle cell disease at the Cavendish Global Health Impact Forum on May 12, 2015 in La Jolla, California.
The Forum, which brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences, takes place May 10-14. Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. For more information, visit: http://cavendishglobal.com
About Emmaus Life Sciences
Emmaus Life Sciences is dedicated to the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The Company’s research on sickle cell disease was initiated by Dr. Niihara at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. The therapy has Orphan Drug designation in the U.S. and Europe and Fast Track designation from the FDA.
For more information, please visit www.emmauslifesciences.com.
Contacts:
Media:
Lori Teranishi for Emmaus Life Sciences, Inc.
510-290-6160
lteranishi@iq360inc.com
Investors:
Matt Sheldon for Emmaus Life Sciences, Inc.
310-279-5975
msheldon@pondel.com
For Cavendish Global:
Alex Charlton
President, Cavendish Global
alex.charlton@cavendishglobal.com
Tel: +1-917-576-1435